Autologous tumour cell vaccine - Champions Oncology/Gradalis/Mary Crowley

Drug Profile

Autologous tumour cell vaccine - Champions Oncology/Gradalis/Mary Crowley

Alternative Names: Bi-shRNAfurin; bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy; FANG vaccine; FANG™; TAG vaccine; TGFbeta2 antisense + rhGMCSF vaccine; Vigil™; Vigil™ EATC

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gradalis
  • Developer Gradalis; Mary Crowley Cancer Research Center
  • Class Cancer vaccines; Tumour cell vaccines
  • Mechanism of Action Furin expression inhibitors; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II/III Breast cancer
  • Phase II Ewing's sarcoma; Gynaecological cancer; Liver metastases; Malignant melanoma
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal, Injection)
  • 01 Sep 2017 Gradalis completes a phase I trial in Malignant melanoma (Second-line therapy or greater, Combination therapy) in USA (NCT02574533)
  • 28 Jul 2017 Gradalis terminates a phase II trial due to a business decision to pursue other indications in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (NCT01453361)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top